Caris Life Sciences, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 |
|---|---|---|---|
| Revenue | $812.0M | $412.3M | $306.1M |
| Operating income | $45.1M | -$257.1M | -$319.6M |
| Cash from operations | $83.2M | -$245.2M | -$276.1M |
| Capital expenditure | $16.3M | $8.4M | $22.3M |
| Free cash flow | $66.9M | -$253.6M | -$298.4M |
| Share repurchases | $113,000 | $0 | $0 |
| Impairments | $0 | $0 | $0 |
| Total assets | $1.1B | $343.7M | — |
| Total liabilities | $548.4M | $620.9M | — |
Shares outstanding 282.7M
Annual filing data through FY ended December 31, 2025; float as of July 2, 2026.